Enhanced endogenous type I interferon cell-driven survival and inhibition of spontaneous apoptosis by Riluzole
- Laboratoire des Interferons/Sarcolectine, Universite Paris Descartes, Centre Universitaire des Saint Peres, 45 Rue des Saints-Peres 75006 Paris (France)
Highly active antiretroviral therapy (HAART), although effective in improving the survival of HIV-1-infected individuals, has not been able to reconstitute the adaptive immune response. We have described the use of novel chemical agents to restore T-cell survival/proliferation by inducing cytokine production. Due to its cationic amphiphilic structure, these molecules appear to enhance immune restoration. In this study, we investigated the action of Riluzole (2-amino-6-trifuromethoxybenzothiazole) in HIV-1 infection. Riluzole is able to increase (effective dose from 1 to 1000 nM) the cell-survival of T cells from HIV-1-infected patients and inhibit spontaneous apoptosis. The immunomodulatory effect of riluzole-sensitized cells was ascribed to endogenous type I interferon (IFN) derived from monocytes. Riluzole might be used for restoring the cell survival of immunocompromised patients and eliminating latent infected cells upon HIV-1 reactivation.
- OSTI ID:
- 21182816
- Journal Information:
- Virology, Vol. 386, Issue 1; Other Information: DOI: 10.1016/j.virol.2008.12.041; PII: S0042-6822(09)00007-5; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0042-6822
- Country of Publication:
- United States
- Language:
- English
Similar Records
Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation
Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells